Keenova Therapeutics plc 8-K

What Happened
Keenova Therapeutics plc filed a Form 8-K on June 15, 2026 disclosing that on June 13, 2026 it entered into a purchase agreement to sell its Percocet and Endocet businesses to Par Health, Inc. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions including expiration/termination of the Hart‑Scott‑Rodino waiting period.

Key Details

• Total expected consideration: approximately $250 million.
• Upfront cash at closing: $25 million (subject to customary cash, debt and working capital adjustments).
• Remaining consideration: quarterly cash earnout payments tied to the Business’s gross profit over five years following closing.
• Post-closing: Keenova will no longer market, manufacture or distribute opioid products.

Why It Matters
This is a material divestiture of Keenova’s opioid product lines (Percocet and Endocet) that will change the company’s product mix and opioid exposure. The deal provides immediate cash at closing and potential future cash via earnouts, but final amounts depend on future gross profits and satisfaction of closing conditions, including regulatory clearance. Investors should note the filing’s forward‑looking statements and the risks described in Keenova’s SEC filings for factors that could affect timing and actual proceeds.